EUVIMEDEUVIMED entdecken
Open Access

Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots

Josef Dib, Laura Tretzel, Thomas Piper, Andreas Lagojda, Dirk Kuehne, Wilhelm Schänzer, Mario Thevis

Clinical Mass Spectrometry · 2017

DOI: 10.1016/j.clinms.2017.10.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Mass Spectrometry, 2017. Verfasst von Josef Dib und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, German…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Antidoping Switzerland, Federal Ministry of the Interior of the Federal Republic of Germany Bonn, Manfred-Donike-Institute for Doping Analysis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AdipoRon and 112254 represent two known synthetic adiponectin receptor (adipoR) agonists. Although AdipoRon is the more potent compound, both have physiological properties that are similar to adiponectin - an adipokine with antidiabetic and antiatherogenic effects. Several transcriptional regulators are activated by adipoR-agonists leading to increased mitochondrial DNA content in vitro, an effect that can be abused by athletes for performance enhancing purposes. In the context of preventive anti-doping research, detection of AdipoRon and 112254 in routine doping control specimens would be valuable. Here, we describe our process for incorporating AdipoRon and 112254 into routine doping control methods involving urine and dried blood spot (DBS) analysis. Method validation including evaluation of specificity, limit of detection, identification capability, carryover, matrix interference, recovery, interday and intraday precision and linearity to standards provided by WADA. For identification in human urine, a liquid chromatography-tandem mass spectrometry-based testing approach was implemented for both adipoR agonists and two respective phase-I metabolites. Recovery of 85-104%, satisfactory limits of detection (i.e., 0.5-1 ng/mL), and imprecision values over three days at three concentration levels of

Schlagwörter

Stichwörter der Autor:innen

AdipoRonAdipor agonistsDopingExercise mimeticMass spectrometrySport

Autor:innen und Institutionen

  • Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
  • Bayer AG, Crop Science Division, Alfred-Nobel-Str. 50, 40789 Monheim, Germany.
  • European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.

Förderung

  • Antidoping Switzerland
  • Federal Ministry of the Interior of the Federal Republic of Germany Bonn
  • Manfred-Donike-Institute for Doping Analysis

Zitieren

APA

Dib, J., Tretzel, L., Piper, T., Lagojda, A., Kuehne, D., Schänzer, W., & Thevis, M. (2017). Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots. Clinical Mass Spectrometry. https://doi.org/10.1016/j.clinms.2017.10.002

Vancouver

Dib J, Tretzel L, Piper T, Lagojda A, Kuehne D, Schänzer W, et al. Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots. Clinical Mass Spectrometry. 2017. doi:10.1016/j.clinms.2017.10.002

BibTeX
@article{Dib2017,
  author = {Dib, Josef and Tretzel, Laura and Piper, Thomas and Lagojda, Andreas and Kuehne, Dirk and Schänzer, Wilhelm and Thevis, Mario},
  title = {Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots},
  journal = {Clinical Mass Spectrometry},
  year = {2017},
  doi = {10.1016/j.clinms.2017.10.002}
}
Kostenlos starten →